Abstract:Tumors create a unique immunosuppressive microenvironment (tumor microenvironment, TME) whereby leukocytes are recruited into the tumor by various chemokines and growth factors. However, once in the TME, these cells lose the ability to promote anti-tumor immunity and begin to support tumor growth and down-regulate anti-tumor immune responses. Studies on tumor-associated leukocytes have mainly focused on cells isolated from tumor-draining lymph nodes or spleen due to the inherent difficulties in obtaining sufficient cell numbers and purity from the primary tumor. While identifying the mechanisms of cell activation and trafficking through the lymphatic system of tumor bearing mice is important and may give insight to the kinetics of immune responses to cancer, in our experience, many leukocytes, including dendritic cells (DCs), in tumor-draining lymph nodes have a different phenotype than those that infiltrate tumors. Furthermore, we have previously demonstrated that adoptively-transferred T cells isolated from the tumor-draining lymph nodes are not tolerized and are capable of responding to secondary stimulation in vitro unlike T cells isolated from the TME, which are tolerized and incapable of proliferation or cytokine production. Interestingly, we have shown that changing the tumor microenvironment, such as providing CD4(+) T helper cells via adoptive transfer, promotes CD8(+) T cells to maintain pro-inflammatory effector functions. The results from each of the previously mentioned studies demonstrate the importance of measuring cellular responses from TME-infiltrating immune cells as opposed to cells that remain in the periphery. To study the function of immune cells which infiltrate tumors using the Miltenyi Biotech isolation system, we have modified and optimized this antibody-based isolation procedure to obtain highly enriched populations of antigen presenting cells and tumor antigen-specific cytotoxic T lymphocytes. The protocol includes a detailed dissection of murine prostate tissue from a spontaneous prostate tumor model (TRansgenic Adenocarcinoma of the Mouse Prostate -TRAMP) and a subcutaneous melanoma (B16) tumor model followed by subsequent purification of various leukocyte populations.

Isolation and Analysis of Tumor-Infiltrating Treg

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Isolation of Immune Cells from Primary Tumors.

Tumor infiltrating lymphocytes are enriched for highly suppressive CD4+Foxp3+regulatory T cells compared to peripheral blood: a flow cytometric analysis of two distinct cancer types

Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity

Tumor-infiltrating Regulatory T Cells: Origins and Features

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Regulatory T cells in tumor immunity

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Profile of Regulatory T Cells and Interferon Γ Secretion in the Tumor-Draining Lymph Node from Mouse Hepa1–6 Cells

Regulatory T Cell and Tumor Immunity

Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy

Immunoregulatory T cells in tumor immunity

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

Conversion of CCL18-recruited Naïve CD4+ T Cells to Tumor-Infiltrating Regulatory T Cells in Breast Cancer and Suppression of Antitumor Immunity.

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells

Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting

The progression of regulatory T cells and tumor immunity

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting